尿失禁治療薬の市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、性別、流通チャネル別、地域別、セグメント予測、2024年～2030年

市場規模と動向

尿失禁治療薬の世界市場規模は、2023年に43億7,000万米ドルと推定され、高齢化社会における尿失禁（UI）の有病率の増加と、利用可能な治療薬法に関する認知度の高まりにより、2024～2030年にかけてCAGR 4.0％で拡大すると予測されています。Dovepressの2023年5月の報告書によると、女性の尿失禁有病率は24.8％で、ストレス性尿失禁が12.7％と最も多く、次いで混合性尿失禁が8.0％、切迫性尿失禁が4.1％でした。この研究では、UIの有病率は年齢や体格指数（BMI）とともに徐々に増加することが強調されました。

この市場には、抗コリン薬、β3アドレナリン作動薬、局所エストロゲンなど様々な薬剤が含まれています。これらの薬剤は、膀胱の収縮を抑え、膀胱の容量を増やし、尿道や膣の組織を強化することで症状を管理するのに役立ちます。市場各社は、より効果的で安全な治療薬を導入するために研究開発に継続的に投資しており、これが市場の成長を促進しています。

高齢化はこの市場の成長を大きく後押ししています。世界の平均寿命の伸びに伴い、高齢者の数が増加し、UIを含む加齢関連疾患の有病率の上昇につながっています。高齢者は、骨盤底筋の衰え、膀胱容量の減少、排尿機能に影響を与えるその他の健康状態により、膀胱制御の問題を経験することが多いです。この人口動態の変化は、これらの症状を管理・緩和するための治療薬ソリューションに対する需要の高まりに大きく寄与しています。

世界的に、60歳以上の人口は2020年の10億人から2050年には21億人に倍増すると予測されています。人口の高齢化に伴い、転倒やせん妄のようなUIやその他の高齢者症候群の負担は増大すると予想されます。この増加により、より効果的で利用しやすい治療薬が必要となり、このセグメントの研究開発が推進されています。その結果、医療プロバイダーはUIのより良い管理を通じて高齢者の生活の質を向上させることに注力しています。その結果、市場は拡大し、各社はこの増加する患者集団のニーズを満たすために革新的な治療薬に投資しています。

さらに、医薬品開発の進歩もこの市場の成長に大きく寄与しています。研究者や製薬会社は、より優れた有効性、より少ない副作用、改良されたデリバリー方法を持つ新薬の開発に注力しています。徐放性製剤や併用療法などの技術革新により、患者のコンプライアンスと治療薬成績が向上しています。例えば、2024年4月、Lupin Ltdは米国で過活動膀胱の管理を目的としたマイベトリクのジェネリック代替品であるミラベグロンを発売しました。さらに、新規の薬剤標的や作用機序の探求は、より効果的な治療薬法の導入につながっています。こうした進歩は、患者のQOLを向上させるだけでなく、優れた治療薬選択肢を提供することで市場拡大の原動力にもなっています。

さらに、近年、尿失禁に対する認識と診断が顕著に高まっています。医療機関や製薬会社による健康キャンペーンや教育プログラムは、この症状に関連する偏見を減らし、医療機関に相談するよう促す上で重要な役割を果たしています。また、診断ツールや診断方法の改善により、医療従事者が尿失禁のさまざまなタイプを特定・分類することが容易になり、より個別化された効果的な治療薬計画が立てられるようになりました。このような意識の高まりと診断能力の向上により、尿失禁治療薬の患者層が拡大しています。

尿失禁治療薬の世界市場セグメンテーションレポート

本レポートでは、2018～2030年にかけての収益成長を国レベルで予測し、各サブセグメントにおける最新の業界動向と収益機会に関する分析を提供しています。この調査レポートは、世界の尿失禁治療薬市場をタイプ、性別、流通チャネル、薬剤クラス別、地域別に分類しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 尿失禁治療薬市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 尿失禁治療薬市場分析ツール
  • 業界分析-ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 尿失禁治療薬市場：タイプ別、推定・動向分析

• 尿失禁治療薬市場セグメントダッシュボード
• 尿失禁治療薬市場：タイプ別変動分析
• タイプ別尿失禁治療薬市場の展望
• 2018～2030年の市場規模と予測と動向分析
• 腹圧性尿失禁
• 切迫性尿失禁
• 溢流性失禁
• 機能性失禁
• その他

第5章 尿失禁治療薬市場： 薬剤クラス別、推定・動向分析

• 尿失禁治療薬市場セグメントダッシュボード
• 尿失禁治療薬市場：薬剤クラス別変動分析
• 薬剤クラス別尿失禁治療薬市場の展望
• 2018～2030年の市場規模と予測と動向分析
• 抗コリン薬
• ベータ3アドレナリン受容体作動薬
• アルファ遮断薬
• エストロゲン
• デスモプレシン
• 三環系抗うつ薬
• その他

第6章 尿失禁治療薬市場：流通チャネル別、推定・動向分析

• 尿失禁治療薬市場セグメントダッシュボード
• 尿失禁治療薬市場：流通チャネル別変動分析
• 流通チャネル別尿失禁治療薬市場の展望
• 2018～2030年の市場規模と予測と動向分析
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 尿失禁治療薬市場：性別、推定・動向分析

• 尿失禁治療薬市場セグメントダッシュボード
• 尿失禁治療薬市場：性別変動分析
• 性別尿失禁治療薬市場展望
• 2018～2030年の市場規模と予測と動向分析
• 男性
• 女性

第8章 尿失禁治療薬市場：地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Johnson &Johnson
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • Ferring Pharmaceuticals

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 4. Global urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 5. Global urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 6. Global urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 7. North America urinary incontinence therapeutics market, by region, 2018 - 2030, (USD Billion)
• Table 8. North America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 9. North America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 10. North America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 11. North America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 12. U.S. urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 13. U.S. urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 14. U.S. urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 15. U.S. urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 16. Canada urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 17. Canada urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 18. Canada urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 19. Canada urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 20. Mexico urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 21. Mexico urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 22. Mexico urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 23. Mexico urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 24. Europe urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
• Table 25. Europe urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 26. Europe urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 27. Europe urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 28. Europe urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 29. UK urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 30. UK urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 31. UK urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 32. UK urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 33. Germany urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 34. Germany urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 35. Germany urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
• Table 36. Germany urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 37. France urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 38. France urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 39. France urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
• Table 40. France urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 41. Italy urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 42. Italy urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 43. Italy urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 44. Italy urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 45. Spain urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 46. Spain urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 47. Spain urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 48. Spain urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 49. Denmark urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 50. Denmark urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 51. Denmark urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
• Table 52. Denmark urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 53. Norway urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 54. Norway urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 55. Norway urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 56. Norway urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 57. Sweden urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 58. Sweden urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 59. Sweden urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 60. Sweden urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 61. Asia Pacific urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
• Table 62. Asia Pacific urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 63. Asia Pacific urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 64. Asia Pacific urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 65. Asia Pacific urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 66. Japan urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 67. Japan urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 68. Japan urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 69. Japan urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 70. China urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 71. China urinary incontinence therapeutics market, by gender 2018 - 2030, (USD Billion)
• Table 72. China urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
• Table 73. China urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 74. India urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 75. India urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 76. India urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 77. India urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 78. Australia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 79. Australia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 80. Australia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 81. Australia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 82. South Korea urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 83. South Korea urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 84. South Korea urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 85. South Korea urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 86. Thailand urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 87. Thailand urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 88. Thailand urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 89. Thailand urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 90. Latin America urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
• Table 91. Latin America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 92. Latin America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 93. Latin America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 94. Latin America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 95. Brazil urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 96. Brazil urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 97. Brazil urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 98. Brazil urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 99. Argentina urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 100. Argentina urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 101. Argentina urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 102. Argentina urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 103. Middle East & Africa urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
• Table 104. Middle East & Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 105. Middle East & Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 106. Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 107. Middle East & Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 108. South Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 109. South Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 110. South Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 111. South Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 112. Saudi Arabia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 113. Saudi Arabia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 114. Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 115. Saudi Arabia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 116. UAE urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 117. UAE urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 118. UAE urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 119. UAE urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
• Table 120. Kuwait urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
• Table 121. Kuwait urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
• Table 122. Kuwait urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
• Table 123. Kuwait urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)

List of Figures

• Fig. 1. Information procurement
• Fig. 2. Primary research pattern
• Fig. 3. Market research approaches
• Fig. 4. Value chain-based sizing & forecasting
• Fig. 5. Market formulation & validation
• Fig. 6. Urinary incontinence therapeutics market segmentation
• Fig. 7. Market driver analysis (current & future impact)
• Fig. 8. Market restraint analysis (current & future impact)
• Fig. 9. SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 10. Porter's five forces analysis
• Fig. 11. Urinary incontinence therapeutics market, type outlook key takeaways (USD billion)
• Fig. 12. Urinary incontinence therapeutics market: type movement analysis (USD billion), 2023 & 2030
• Fig. 13. Stress incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 14. Urge incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 15. Overflow Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 16. Functional Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 17. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 18. Urinary incontinence therapeutics market, gender outlook key takeaways (USD billion)
• Fig. 19. Urinary incontinence therapeutics market: gender movement analysis (USD billion), 2023 & 2030
• Fig. 20. Male market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 21. Female market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 22. Urinary incontinence therapeutics market, distribution channel outlook key takeaways (USD billion)
• Fig. 23. Urinary incontinence therapeutics market: distribution channel movement analysis (USD billion), 2023 & 2030
• Fig. 24. Hospital pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 25. Retail pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 26. Online pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 27. Urinary incontinence therapeutics market, drug class outlook key takeaways (USD billion)
• Fig. 28. Urinary incontinence therapeutics market: drug class movement analysis (USD billion), 2023 & 2030
• Fig. 29. Anticholinergics market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 30. Beta-3 adrenoceptor agonists market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 31. Alpha blockers market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 32. Estrogen market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 33. Desmopressin market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 34. Tricyclic antidepressants market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 35. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 36. Urinary incontinence therapeutics market: regional key takeaways (USD billion)
• Fig. 37. Urinary incontinence therapeutics market: regional outlook, 2023 & 2030, USD billion
• Fig. 38. North America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 39. U.S. urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 40. Canada urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 41. Mexico urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 42. Europe urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 43. UK urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 44. Germany urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 45. France urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 46. Spain urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 47. Italy urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 48. Norway urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 49. Denmark urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 50. Sweden urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 51. Asia Pacific urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 52. China urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 53. Japan urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 54. India urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 55. South Korea urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 56. Australia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 57. Thailand urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 58. Latin America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 59. Brazil urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 60. Argentina urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 61. Middle East and Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 62. South Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 63. Saudi Arabia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 64. UAE urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 65. Kuwait urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
• Fig. 66. List of key emerging company's/distribution channel disruptors/innovators

Market Size & Trends

The global urinary incontinence therapeutics market size was estimated at USD 4.37 billion in 2023 and is projected to expand at a CAGR of 4.0% from 2024 to 2030 due to the increasing prevalence of urinary incontinence (UI) among aging populations and the rising awareness about available treatments. According to a May 2023 report by Dovepress, the prevalence of female UI was found to be 24.8%, with stress UI being the most common subtype at 12.7%, followed by mixed UI at 8.0%, and urgency UI at 4.1%. The study highlighted that the prevalence of UI increased progressively with age and body mass index (BMI).

This market includes a variety of medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogens. These drugs help manage symptoms by reducing bladder contractions, increasing bladder capacity, and strengthening urethral and vaginal tissues. Market players are continuously investing in research and development to introduce more effective and safer treatments, which is propelling market growth.

The aging population is majorly driving the growth of this market. As global life expectancy increases, the number of elderly individuals is rising, leading to a higher prevalence of age-related conditions, including UI. Older adults often experience bladder control issues due to weakened pelvic floor muscles, decreased bladder capacity, and other health conditions that impact urinary function. This demographic shift significantly contributes to the growing demand for therapeutic solutions to manage and alleviate these symptoms.

Globally, the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As the population ages, the burden of UI and other geriatric syndromes like falls and delirium is expected to grow. This increase necessitates more effective and accessible treatments, driving research and development in this sector. Consequently, healthcare providers are focusing on improving the quality of life for older adults through better management of UI. As a result, the market is expanding, with companies investing in innovative treatments to meet the needs of this growing patient population.

In addition, advancements in drug development are significantly contributing to the growth of this market. Researchers and pharmaceutical companies are focusing on developing new drugs with better efficacy, fewer side effects, and improved delivery methods. Innovations such as extended-release formulations and combination therapies are enhancing patient compliance and treatment outcomes. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Mybetriq, aimed at managing overactive bladder in the U.S. Additionally, the exploration of novel drug targets and mechanisms of action is leading to the introduction of more effective therapies. These advancements not only improve the quality of life for patients but also drive market expansion by offering superior treatment options.

Furthermore, there has been a notable increase in awareness and diagnosis of urinary incontinence in recent years. Health campaigns and educational programs by healthcare organizations and pharmaceutical companies have played a crucial role in reducing the stigma associated with this condition and encouraging individuals to seek medical advice. Improved diagnostic tools and methods have also made it easier for healthcare providers to identify and classify different types of urinary incontinence, leading to more personalized and effective treatment plans. This heightened awareness and better diagnostic capabilities are expanding the patient base for UI therapeutics.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, gender, distribution channel, drug class, and region.

• Type Outlook (Revenue, USD Billion; 2018 - 2030)
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Other Types
• Drug Class Outlook (Revenue, USD Billion; 2018 - 2030)
• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen
• Desmopressin
• Tricyclic Antidepressants
• Other Drug Classes
• Gender Outlook (Revenue, USD Billion; 2018 - 2030)
• Male
• Female
• Distribution Channel Outlook (Revenue, USD Billion; 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion; 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Age
  • 1.2.3. Distribution Channel
  • 1.2.4. Drug Class
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Age outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Drug class outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Urinary Incontinence Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Estimates & Trend Analysis

• 4.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 4.2. Urinary Incontinence Therapeutics Market: Type Movement Analysis
• 4.3. Urinary Incontinence Therapeutics Market by Type Outlook (USD Billion)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Stress Incontinence
  • 4.5.1. Stress Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.6. Urge Incontinence
  • 4.6.1. Urge Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.7. Overflow Incontinence
  • 4.7.1. Overflow Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.8. Functional Incontinence
  • 4.8.1. Functional Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.9. Others
  • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Estimates & Trend Analysis

• 5.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 5.2. Urinary Incontinence Therapeutics Market: Drug Class Movement Analysis
• 5.3. Urinary Incontinence Therapeutics Market by Drug Class Outlook (USD Billion)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Anticholinergics
  • 5.5.1. Anticholinergics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Beta-3 Adrenoceptor Agonists
  • 5.6.1. Beta-3 Adrenoceptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Alpha Blockers
  • 5.7.1. Alpha Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Estrogen
  • 5.8.1. Estrogen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Desmopressin
  • 5.9.1. Desmopressin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.10. Tricyclic Antidepressants
  • 5.10.1. Tricyclic Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.11. Others
  • 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Urinary Incontinence Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 6.2. Urinary Incontinence Therapeutics Market: Distribution Channel Movement Analysis
• 6.3. Urinary Incontinence Therapeutics Market by Distribution Channel Outlook (USD Billion)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospital Pharmacies
  • 6.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Retail Pharmacies
  • 6.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Online Pharmacies
  • 6.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Urinary Incontinence Therapeutics Market: Gender Estimates & Trend Analysis

• 7.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 7.2. Urinary Incontinence Therapeutics Market: Gender Movement Analysis
• 7.3. Urinary Incontinence Therapeutics Market by Gender Outlook (USD Billion)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Male
  • 7.5.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Female
  • 7.6.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Pfizer Inc.
    • 9.2.1.1. Company overview
    • 9.2.1.2. Financial performance
    • 9.2.1.3. Age benchmarking
    • 9.2.1.4. Strategic initiatives
  • 9.2.2. AbbVie Inc.
    • 9.2.2.1. Company overview
    • 9.2.2.2. Financial performance
    • 9.2.2.3. Age benchmarking
    • 9.2.2.4. Strategic initiatives
  • 9.2.3. Astellas Pharma Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Age benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. Johnson & Johnson
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Age benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Viatris Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Age benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Teva Pharmaceutical Industries Ltd.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Age benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Sanofi S.A.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Age benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. GlaxoSmithKline plc
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Age benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Age benchmarking
    • 9.2.9.4. Strategic initiatives
    • 9.2.9.5. Strategic initiatives
    • 9.2.9.6. Strategic initiatives
  • 9.2.10. Bayer AG
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Age benchmarking
    • 9.2.10.4. Strategic initiatives
    • 9.2.10.5. Strategic initiatives
  • 9.2.11. Ferring Pharmaceuticals
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Age benchmarking
    • 9.2.11.4. Strategic initiatives
    • 9.2.11.5. Strategic initiatives